Customized for Vaccine Development

Customized for Vaccine Development

Lab scientists in white coats working in a modern, well-lit laboratory setting.

Comprehensive Support Across All Stages of Development

Comprehensive Support Across All

Stages of Development

From early discovery through clinical development and post-licensure, SeromYx’s Systems Serology platform helps vaccine developers understand the functional immune mechanisms that drive protection.

We support natural infection studies, controlled human infection models, field efficacy trials, and post-licensure analyses by identifying functional correlates of protection and immune signatures linked to efficacy. Our data informs critical decisions around antigen and adjuvant selection, dose optimization, manufacturing process changes, and comparison of vaccine candidates against licensed products.

Pathogens Studied Using Systems Serology

Our Systems Serology platform has been applied across a wide range of infectious diseases to support vaccine development, immunogenicity assessment, and immune correlate discovery. The pathogens below represent viruses, bacteria, parasites, and fungi that have been studied using SeromYx’s comprehensive Fc-mediated antibody profiling and functional immune analysis.

  • Viruses (26)

    Coronaviruses

    SARS-CoV-1, SARS-CoV-2, MERS, Common cold coronaviruses (NL63, OC43)

    Flaviviruses & Others

    Dengue, Zika, Yellow fever

    Retroviruses

    HIV, SHIV, SIV, Endogenous retroviruses

    Herpesviruses

    HSV-1, HSV-2, Epstein-Barr virus, Varicella zoster

    Other Viruses

    Influenza, Measles, Mumps, RSV, Hep B, Hep C, HPV, Merkel Cell Polyomavirus, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever

  • Fungus

    Aspergillus spp.

  • Parasite

    Plasmodium falciparum

  • Bacteria (14)

    • Bordetella pertussis
    • Clostridium botulinum
    • Clostridium tetani
    • Corynebacterium diphtheriae
    • Klebsiella pneumoniae
    • Mycobacterium tuberculosis
    • Neisseria meningitidis
    • Pseudomonas aeruginosa
    • Salmonella typhi
    • Shigella spp.
    • Staphylococcus aureus
    • Streptococcus agalactiae
    • Streptococcus pneumoniae
    • Vibrio cholerae

Viruses (26)

Fungi

Parasite

Bacteria (14)

Coronaviruses
SARS-CoV-1, SARS-CoV-2, MERS, Common cold coronaviruses (NL63, OC43)


Flaviviruses & Others
Dengue, Zika, Yellow fever


Retroviruses
HIV, SHIV, SIV, Endogenous retroviruses


Herpesviruses
HSV-1, HSV-2, Epstein-Barr virus, Varicella zoster


Other Viruses
Influenza, Measles, Mumps, RSV, Hep B, Hep C, HPV, Merkel Cell Polyomavirus, Crimean-Congo Hemorrhagic Fever, Rift Valley Fever

Aspergillus spp.

Plasmodium falcioarum

Bordetella pertussis

Clostridium botulinum

Clostridium tetani

Corynebacterium diphtheriae

Klebsiella pneumoniae

Mycobacterium tuberculosis

Neisseria meningitidis

Pseudomonas aeruginosa

Salmonella typhi

Shigella spp.

Staphylococcus aureus

Streptococcus agalactiae

Streptococcus pneumoniae

Vibrio cholerae

DISCOVERY

Systems Serology identifies antibody features linked to disease outcomes.


Profiling hospitalized COVID-19 patients revealed distinct antibody responses: survivors showed a spike (S)-focused, functional profile, while non-survivors had nucleocapsid (N)-biased, less effective antibodies. Just five key antibody features predicted clinical trajectory, supporting early risk stratification and biomarker development. These findings highlight the importance of spike-specific functional antibodies for vaccine targeting.


  • Differentiates survivors and non-survivors using key antibody signatures
  • Links enhanced S-specific phagocytosis and complement activity to protection
  • Informs vaccine antigen selection and immune monitoring strategies
LEARN MORE

LEAD SELECTION

Prioritize candidates by protective antibody functions, not just quantity.


Systems Serology enables comparison of vaccine regimens based on their ability to elicit key protective antibody functions. Screening HIV vaccine candidates revealed wide variation in ADCP levels despite similar antibody titers. Changes in adjuvants and dosing shifted functional profiles, helping developers select candidates that induce higher-quality immune responses. This accelerates confident, data-driven down-selection for clinical advancement.


  • Differentiates vaccine leads by antibody function, not just titer
  • Reveals impact of formulation and regimen on immune quality
  • Supports efficient selection of candidates with greater clinical potential
LEARN MORE

ASSAY DEVELOPMENT, VALIDATION, QUALIFICATION

Robust immune profiling beyond neutralization for clinical trials.


SeromYx developed and qualified a Systems Serology assay under WHO and GCLP standards to measure antibody-dependent functions in SARS-CoV-2 vaccine trials. The assay delivers precise, specific, and sensitive measurement of Fc effector activities (ADCP, ADCD, ADNKA), supporting secondary endpoints in Phase 3 studies and regulatory filings. This validated platform is adaptable for diverse vaccine programs requiring advanced immune monitoring.


  • Ensures reproducible, regulatory-grade immune data across cohorts
  • Measures extra-neutralizing Fc functions linked to protection
  • Scalable qualification framework for broad vaccine applications
LEARN MORE

CLINICAL EFFICACY TESTING

Uncovering antibody mechanisms linked to protection beyond neutralization.


A head-to-head study of mRNA-1273 and BNT162b2 vaccines showed both induced strong humoral responses, but mRNA-1273 elicited higher IgA titers, enhanced Fcγ receptor binding, and greater functional activity (ADNP, ADNKA). Systems Serology mapped distinct Fc effector functions, offering mechanistic insights into their differing real-world efficacy and supporting identification of immune correlates of protection.


  • Differentiates vaccine-induced functional antibody profiles linked to protection
  • Detects spike-specific Fc activities beyond neutralization
  • Provides mechanistic insight for clinical trial correlates and disease attenuation
LEARN MORE

MANUFACTURING SCALE-UP

Integrating antibody avidity with Fc effector profiling to enhance vaccine assessment.


By combining Systems Serology with surface plasmon resonance (SPR)–based avidity measurements, this study uncovered distinct immune profiles differentiating two vaccine manufacturing processes. While one process drove higher effector function with lower avidity, the other generated stronger avidity with reduced effector activity. Multivariate modeling highlighted avidity, NK cell IFNγ responses, and IgG1 as key features distinguishing the processes, providing mechanistic insight into how manufacturing influences vaccine-induced immunity.


  • Links antibody avidity with functional immune readouts
  • Differentiates immune profiles across vaccine manufacturing processes
  • Provides mechanistic insight to guide vaccine design and optimization
LEARN MORE

SCIENTIFIC RESOURCES

By Abigail Harris March 10, 2026
The Fc Review: How do antibody structure and binding dynamics shape ADCC signaling? A recent study in The AAPS Journal explores how multiple antibody design features, including Fab affinity, hinge flexibility, Fc engagement, and antigen density, influence antibody-dependent cellular cytotoxicity (ADCC) signaling. Background: ADCC is a key mechanism of action for many therapeutic antibodies, yet the strength of this response depends on more than Fcγ receptor binding alone. Productive immune activation requires antibodies to bridge target cells and effector cells within the immune synapse, forming receptor crosslinks that trigger downstream signaling. Using a combination of computational modeling and experimental data, this study examines how structural properties of antibodies influence these crosslinking events and ultimately shape ADCC signaling outcomes. The study highlights: ADCC signaling is influenced by multiple antibody properties, including Fab affinity, hinge flexibility, Fc receptor engagement, and antigen expression levels. Antibody structure affects how efficiently Fc receptors and target antigens are crosslinked within the immune synapse. In some cases, moderate Fab affinity supported stronger signaling by favoring productive crosslinking configurations. Antibody valency and hinge flexibility also influenced signaling outcomes by altering the geometry of immune synapse interactions.
February 12, 2026
The Fc Review: How well do our preclinical models capture human Fc biology? A new Science Immunology study takes a deep look at Fcγ receptor and FcRn expression across humans, non-human primates, and mice, highlighting how species-specific differences shape Fc-mediated immune function. Background: Fc-dependent activity is influenced not only by antibody design, but also by where and how Fcγ receptors are expressed across immune cell types and tissues. While animal models remain central to #antibody development, differences in Fcγ receptor biology across species can complicate interpretation of Fc-driven mechanisms. The study highlights: Species-specific differences in Fcγ receptor expression patterns across immune cell subsets and tissues. Context-dependent regulation of Fcγ receptors by inflammatory cues, with expression shifting across cell types and environments. These differences influence how Fc-mediated functions are engaged and interpreted across experimental systems. Cross-species variation in FcγR and FcRn biology helps explain why Fc-dependent effects observed preclinically may not always translate cleanly to human settings. 
January 21, 2026
The Fc Review: How are antibody developers actually using Fc engineering today? A recent analysis of the IMGT/mAb-DB database takes a systematic look at engineered Fc variants across therapeutic antibodies and fusion proteins, offering a real-world snapshot of how Fc design choices are being deployed in the clinic. Background: Fc engineering is often discussed in terms of individual mutations or isolated use cases. But at an industry level, it’s less clear how frequently Fc variants are used, which functions are prioritized, and whether antibodies rely on single or multiple Fc modifications. By mining curated entries in IMGT/mAb-DB, this study steps back to examine Fc engineering trends across approved and clinical-stage molecules. The review highlights: Fc engineering is widespread across therapeutic antibodies and fusion proteins cataloged in IMGT/mAb-DB Effector silencing strategies are commonly employed, particularly in programs prioritizing safety and controlled immune engagement Many molecules incorporate multiple Fc variants, rather than a single engineered change Fc modifications are used across a range of mechanisms and formats, underscoring Fc’s role as an intentional design lever

Frequently Asked Questions (FAQ)

  • Can you analyze clinical trial samples?

    Yes. Our platform supports preclinical through clinical-stage vaccine programs, including natural infection studies, controlled human infection models, and field efficacy trials.

  • Can you identify immune signatures associated with protection?

    Yes. Using systems-level analytics, we identify multivariate immune features that associate with protection, durability, or reduced disease severity.

  • When is the best time to engage SeromYx in a program?

    We provide value across all phases, but especially during:

    • Candidate down-selection
    • Phase I/II immunogenicity studies
    • Correlate of protection investigations
  • What are the sample requirements for vaccine studies?

    Sample volume requirements vary depending on the assay panel selected. In general, we require approximately 25–150 µL per assay when performed in isolation against a single antigen.


    When multiple assays are combined within an integrated panel, overall sample requirements may decrease due to optimized assay design.


    If sample volume is limited, particularly for clinical trial cohorts, we can develop a tailored strategy to maximize data generation while conserving material. We encourage teams to contact us for a study-specific estimate as it may fall outside the range provided above.